A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

Self-treatment of acute paroxysmal supraventricular tachycardia (SVT) with a nasal spray containing a short-acting calcium-channel blocker is likely to be possible with a high rate of conversion to ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that the U.S. Food and Drug Administration has approved its first commercial product, CARDAMYST (etripamil) nasal spray. The prescription ...

HealthDay News — An experimental nasal spray, etripamil, may benefit patients with paroxysmal supraventricular tachycardia (PSVT), according to a study presented at the annual meeting of the Heart ...

Supported by a grant (HE 12373) from the Public Health Service and a grant from the San Diego County Heart Association. We are indebted to Dr. David B. Carmichael, who referred the patient for ...